Trials / Terminated
TerminatedNCT04602065
Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial
Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type), a Multicenter, Open-label Phase Ib/II Trial
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of IBI318 monotherapy for relapsed/refractory extranodal NK/T cell lymphoma (nasal type).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody) | IBI318, 300mg, Q2W, Intravenous influsion. |
Timeline
- Start date
- 2020-11-24
- Primary completion
- 2023-02-28
- Completion
- 2023-02-28
- First posted
- 2020-10-26
- Last updated
- 2023-03-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04602065. Inclusion in this directory is not an endorsement.